In the last trading session, 2.88 million shares of the Ventyx Biosciences Inc (NASDAQ:VTYX) were traded, and its beta was 0.32. Most recently the company’s share price was $1.77, and it changed around -$0.1 or -5.35% from the last close, which brings the market valuation of the company to $118.81M. VTYX currently trades at a discount to its 52-week high of $11.48, offering almost -548.59% off that amount. The share price’s 52-week low was $1.79, which indicates that the current value has fallen by an impressive -1.13% since then. We note from Ventyx Biosciences Inc’s average daily trading volume that its 10-day average is 1.01 million shares, with the 3-month average coming to 1.17 million.
Ventyx Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended VTYX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Ventyx Biosciences Inc is expected to report earnings per share of -0.54 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ventyx Biosciences Inc (NASDAQ:VTYX) trade information
Instantly VTYX has showed a red trend with a performance of -5.35% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.2100 on recent trading dayincreased the stock’s daily price by 19.91%. The company’s shares are currently down -28.34% year-to-date, but still down -17.67% over the last five days. On the other hand, Ventyx Biosciences Inc (NASDAQ:VTYX) is -30.31% down in the 30-day period. We can see from the shorts that 8.14 million shares have been sold at a short interest cover period of 9.91 day(s).
The consensus price target as assigned by Wall Street analysts is $45, which translates to bulls needing to increase their stock price by 96.07% from its current value. Analyst projections state that VTYX is forecast to be at a low of $6 and a high of $60.
Ventyx Biosciences Inc (VTYX) estimates and forecasts
Ventyx Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -63.35 percent over the past six months and at a 36.36% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 31.10% in revenue this quarter, and will report an increase of 12.90% in the next quarter.
Forecasts for the next quarter put sales growth at �.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -148.81%.
VTYX Dividends
Ventyx Biosciences Inc’s next quarterly earnings report is expected to be released in December.
Ventyx Biosciences Inc (NASDAQ:VTYX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.31% of Ventyx Biosciences Inc shares, and 85.21% of them are in the hands of institutional investors. The stock currently has a share float of 88.13%. Ventyx Biosciences Inc stock is held by 168.0 institutions, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) being the largest institutional investor. By 2024-06-30, it held 9.4284% of the shares, which is about 5.83 million shares worth $13.47 million.
CITADEL ADVISORS LLC, with 9.3133% or 5.76 million shares worth $13.3 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
